

0960-894X(95)00559-5

## ALCOHOL INVERSION OF 17 $\beta$ -STEROIDS


Jeffrey A. Dodge,\* and Charles W. Lugar III


*Lilly Research Laboratories  
 Eli Lilly and Company  
 Indianapolis, IN 46285*

**Abstract:** Inversion of 17 $\beta$ -steroids has been accomplished using a modified Mitsunobu protocol in which 4-nitrobenzoic acid is employed as the acidic component. Excellent yields of inverted product were obtained for a number of representative steroid families including estrogens, equilenins, and androgens. Application of this methodology to the synthesis of 17 $\alpha$ -dihydroequilenin is described.

The stereochemistry at the 17-position of sex steroids plays a key role in dictating the molecular interactions between a given hormone and its receptor. For example, 17 $\alpha$ -estradiol binds with an order of magnitude less affinity to the estrogen receptor than its 17 $\beta$ -counterpart (see steroid numbering system in 3).<sup>1</sup> Interestingly, one consequence of this phenomenon is a time-dependent mixed agonism-antagonism of the physiological functions of 17 $\beta$ -estradiol.<sup>2</sup> From a structure-activity standpoint, while 17 $\beta$ -steroidal alcohols are readily accessible via selective reduction of the corresponding ketones,<sup>3</sup> preparation of 17 $\alpha$ -alcohols has proven somewhat problematic.<sup>4</sup> This is particularly true when Mitsunobu inversion conditions<sup>5</sup> (diethylazodicarboxylate, PPh<sub>3</sub>, RCO<sub>2</sub>H) are employed.<sup>6</sup> Significantly, only a limited number of reports employing this mild, essentially neutral, protocol have been documented and in each of these cases, poor<sup>7</sup> to negligible yields<sup>4</sup> of 17 $\alpha$ -inverted product are observed. To address this issue, we have investigated the use of a modified Mitsunobu protocol to efficaciously prepare 17 $\alpha$ -steroids.

Our interest in this area stemmed from the need for multigram quantities of 17 $\alpha$ -dihydroequilenin (a non-uterotrophic component of Premarin<sup>8</sup>) for pharmacological evaluation in our animal models. The prohibitive (\$3000/g) cost of 3 prompted us to examine Mitsunobu inversion of 2, readily available from (+)-equilenin (1). Since the introduction of the Mitsunobu reaction in 1967,<sup>1</sup> numerous variants of the standard reagent protocol have been reported including changes in the azodicarboxylate,<sup>9</sup> phosphine,<sup>10</sup> and acidic components.<sup>11,12</sup> Work from our own laboratories<sup>13</sup> has indicated sterically encumbered alcohols can be easily inverted employing relatively acidic carboxylic acids such as 4-nitrobenzoic acid. Thus, it seemed likely use of this modification would provide access to the requisite D-ring  $\alpha$  stereochemistry. Gratifyingly, when 2 was subjected to these modified Mitsunobu conditions (2.5 eq. 4-nitrobenzoic acid, PPh<sub>3</sub>, and DEAD, respectively) followed by heating the reaction mixture to 80 °C for 1.5 h in toluene, the desired *p*-nitrobenzoate ester was isolated in 75 % yield. Removal of the silyl protecting group and saponification of the ester provided the





desired product (3) which was identical in all respects with an authentic sample. In an effort to generalize this methodology, a variety of steroidal frameworks were subsequently examined (Scheme I).<sup>14</sup> In all cases, efficacious inversion of the 17 $\beta$ -position was observed regardless of steroid class, i.e., estrogens (4, 5), equilenins (6), and androgens (7–9), all proved amenable to the protocol employed. In addition, a variety of protecting groups including silyl (TBDMS, TBDPS), ester (acetate, benzoate), and ether (Me) functionality were well-tolerated.

In summary, modified Mitsunobu reaction conditions employing 4-nitrobenzoic acid as the coupling partner allow for efficacious alcohol inversion of the 17 $\beta$ -position in the steroid nucleus. These conditions appear general to various families of steroid hormones and represent a substantial improvement in current synthetic technology.

#### References and Notes

- Ojasoo, T.; Raynaud, J. P.; Dore, J. C. *J. Steroid Biochem. Molec. Biol.* **1994**, *48*, 31.
- Clark, J. H.; Markaverich, B. M. *Pharmacol. Ther.* **1982**, *21*, 429.
- Reduction of 17-ketones occurs exclusively from the  $\alpha$ -face to provide the corresponding 17 $\beta$ -alcohol. See Feiser, L. F.; Fieser, M., Ed., *Steroids*, Reinhold Publishing Corporation, New York, 1959, p 444.
- Bose, A. K.; Lal, B.; Hoffman, W. A.; Manhas, M. S. *Tetrahedron Lett.* **1973**, *18*, 1619.
- (a) Mitsunobu, O. *Synthesis* **1981**, 1. (b) Hughes, D. L. *Org. React.* **1992**, *42*, 335. (c) Castro, B. R. *Org. React.* **1983**, *29*, 1.
- For reasons that are not entirely clear, increases in yields under Mitsunobu conditions have been reported in the steroid nucleus when benzene is used as the solvent. See Loibner, H.; Zbiral, E. *Helv. Chim. Acta* **1977**, *60*, 417.
- (a) Gabbard, R. B.; Segaloff, A. *Steroids* **1963**, *42*, 3195. (b) Breslow, R.; Corcoran, R. J.; Snider, B. B.; Doll, R. J.; Khanna, P. L.; Kayala, R. *J. Am. Chem. Soc.* **1977**, *99*, 905.
- Washburn, S. A.; Adams, M. R.; Clarkson, T. B.; Adelman, S. J. *Am. J. Obstet. Gynecol.* **1993**, *169*, 251.
- For example see (a) Tsunoda, T.; Yamamiya, Y.; Kawamura, Y.; Ito, S. *Tetrahedron Lett.* **1995**, *36*, 2529. (b) Tsunoda, T.; Nagaku, M.; Nagino, C.; Kawamura, Y.; Ozaki, F.; Hioki, H.; Ito, S. *Tetrahedron Lett.* **1995**, *36*, 2531.
- Hughes, D. L.; Reamer, R. A.; Bergan, J. J.; Grabowski, E. J. J. *J. Am. Chem. Soc.* **1968**, *110*, 6487.
- (a) Saiah, M.; Beasodes, M.; Antonakis, K. *Tetrahedron Lett.* **1992**, *33*, 4317. (b) Martin, S. F.; Dodge, J. A.; *Tetrahedron Lett.* **1991**, *32*, 3017.
- For other variations see (a) Tsunoda, T.; Ozaki, F.; Ito, S. *Tetrahedron Lett.* **1994**, *35*, 5081. (b) Castro, J. L.; Matassa, V. G. *J. Org. Chem.* **1994**, *59*, 2289.
- Dodge, J. A.; Trujillo, J. I.; Presnell, M. J. *Org. Chem.* **1994**, *59*, 234.
- All new compounds exhibited appropriate <sup>1</sup>H-NMR, IR, MS and/or elemental analysis.